LivaNova PLC (NASDAQ:LIVN) Short Interest Down 16.6% in February

LivaNova PLC (NASDAQ:LIVN) was the recipient of a significant decline in short interest during the month of February. As of February 13th, there was short interest totaling 2,032,704 shares, a decline of 16.6% from the January 29th total of 2,436,767 shares. Approximately 3.7% of the shares of the company are sold short. Based on an average daily trading volume, of 676,965 shares, the days-to-cover ratio is presently 3.0 days. Based on an average daily trading volume, of 676,965 shares, the days-to-cover ratio is presently 3.0 days. Approximately 3.7% of the shares of the company are sold short.

LivaNova Price Performance

NASDAQ LIVN traded down $1.26 during midday trading on Thursday, hitting $64.00. The company had a trading volume of 269,526 shares, compared to its average volume of 760,879. The firm has a 50-day moving average price of $65.03 and a 200-day moving average price of $59.40. The company has a market capitalization of $3.50 billion, a PE ratio of -14.33 and a beta of 0.92. The company has a current ratio of 1.36, a quick ratio of 1.16 and a debt-to-equity ratio of 0.29. LivaNova has a twelve month low of $32.48 and a twelve month high of $71.92.

LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, February 25th. The company reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.80 by $0.06. The company had revenue of $360.86 million for the quarter, compared to analyst estimates of $354.31 million. LivaNova had a positive return on equity of 16.54% and a negative net margin of 17.46%.LivaNova’s quarterly revenue was up 12.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.81 EPS. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. As a group, analysts anticipate that LivaNova will post 2.85 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on LIVN. Wall Street Zen raised LivaNova from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 20th. Mizuho lifted their price objective on shares of LivaNova from $70.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. Stifel Nicolaus set a $80.00 price objective on shares of LivaNova in a research report on Wednesday, February 25th. Needham & Company LLC lifted their target price on shares of LivaNova from $64.00 to $81.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Finally, The Goldman Sachs Group reiterated a “neutral” rating and issued a $66.00 price target on shares of LivaNova in a research note on Friday, January 9th. Seven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $74.78.

Institutional Trading of LivaNova

A number of institutional investors and hedge funds have recently made changes to their positions in LIVN. Pacer Advisors Inc. increased its stake in LivaNova by 131.7% in the fourth quarter. Pacer Advisors Inc. now owns 16,661 shares of the company’s stock valued at $1,025,000 after acquiring an additional 9,471 shares during the last quarter. Invesco Ltd. boosted its holdings in shares of LivaNova by 4.5% in the 4th quarter. Invesco Ltd. now owns 1,091,086 shares of the company’s stock valued at $67,135,000 after purchasing an additional 47,323 shares in the last quarter. Corient Private Wealth LLC acquired a new stake in shares of LivaNova in the 4th quarter valued at $604,000. Mercer Global Advisors Inc. ADV bought a new position in shares of LivaNova in the 4th quarter valued at $306,000. Finally, State of Tennessee Department of Treasury raised its holdings in shares of LivaNova by 44.9% during the 4th quarter. State of Tennessee Department of Treasury now owns 30,304 shares of the company’s stock worth $1,991,000 after buying an additional 9,396 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.